Table 5.
Correlations between opioid medication dose at time of delivery and neonatal abstinence syndrome (NAS) parameters
| Correlation of daily dose with | Standard protocol (n=77)
|
Clinical trial (n=37)
|
||||||
|---|---|---|---|---|---|---|---|---|
| Mean maternal methadone dose (n=51) | Mean maternal buprenorphine dose (n=26) | Mean maternal methadone dose (n=19) | Mean maternal buprenorphine dose (n=18) | |||||
|
|
|
|
|
|||||
| r | p | r | p | r | p | r | p | |
| Occurrence of medicated NAS | −0.03 | 0.851 | −0.21 | 0.298 | 0.23 | 0.338 | 0.35 | 0.154 |
| Peak NAS score | 0.01 | 0.936 | −0.14 | 0.501 | 0.12 | 0.613 | 0.33 | 0.176 |
| Total morphine dose for NAS (in mg) | −0.04 | 0.789 | 0.13 | 0.528 | 0.36 | 0.129 | 0.30 | 0.225 |
| Duration of NAS treatment (in days) | 0.11 | 0.466 | 0.06 | 0.783 | 0.35 | 0.145 | 0.36 | 0.142 |